Having trouble accessing articles? Reset your cache.

VGX-3100: Phase I data

Data from an open-label, dose-escalation, U.S. Phase I trial showed that 13 of 18 women with a previous history of cervical

Read the full 215 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE